First Approved Self-amplifying COVID-19 Vaccine Publishes Positive Study Results – Precision Vaccinations

(Precision Vaccinations News)

CSL and Arcturus Therapeutics today announce the journal Nature Communicationshas published results from an integrated phase 1/2/3a/3b study evaluating the safety, immunogenicity, and efficacy of ARCT-154, a novel self-amplifying (sa-mRNA) COVID-19 vaccine.

ARCT-154 is the world's first approved sa-mRNA COVID-19 vaccine for use in Japan.

The joint study's results demonstrate that two 5 g doses of ARCT-154, sa-mRNA vaccine, were well-tolerated, immunogenic, and provided significant protection against multiple strains of COVID-19.

The efficacy of ARCT-154 against severe COVID-19 was 100%in healthy persons aged 18-59 and more than 90%in persons at risk of severe consequences of the disease due to co-morbidities or older age.

"The results published inNature Communicationsdemonstrate the efficacy and tolerability of ARCT-154 and add to a growing body of evidence that our sa-mRNA vaccine has the potential to provide significant protection against the pervasive virus, reinforcing our promise to protect public health," said Jon Edelman, M.D., Senior Vice President, Vaccines Innovation Unit, CSL, in a press release on May 20, 2024.

Unlike standard mRNA vaccines, sa-mRNA vaccines instruct the body to make more mRNA and protein to boost the immune response.

CSL is a global biotechnology company with aportfolio of medicines and vaccines.

See more here:

First Approved Self-amplifying COVID-19 Vaccine Publishes Positive Study Results - Precision Vaccinations